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A B S T R A C T
Using subunit vaccines, e.g., based on peptide or protein antigens, to teach the immune system to kill abnormal
host cells via induction of cytotoxic T lymphocytes (CTL) is a promising strategy against intracellular infections
and cancer. However, customized adjuvants are required to potentiate antigen-speciﬁc cellular immunity. One
strong CTL-inducing adjuvant is the liposomal cationic adjuvant formulation (CAF)09, which is composed of
dimethyldioctadecylammonium (DDA) bromide, monomycoloyl glycerol (MMG) analogue 1 and poly-
inosinic:polycytidylic acid [poly(I:C)]. However, this strong CTL induction requires intraperitoneal adminis-
tration because the vaccine forms a depot at the site of injection (SOI) after subcutaneous (s.c.) or intramuscular
(i.m.) injection, and depot formation impedes the crucial vaccine targeting to the cross-presenting dendritic cells
(DCs) residing in the lymph nodes (LNs). The purpose of the present study was to investigate the eﬀect of
polyethylene glycol (PEG) grafting of CAF09 on the ability of the vaccine to induce antigen-speciﬁc CTL re-
sponses after s.c. administration. We hypothesized that steric stabilization and charge shielding of CAF09 by
PEGylation may reduce depot formation at the SOI and enhance passive drainage to the LNs, eventually im-
proving CTL induction. Hence, the vaccine (antigen/CAF09) was post-grafted with a novel type of anionic
PEGylated peptides based on GDGDY repeats, which were end-conjugated with one or two PEG1000 moieties,
resulting in mono- and bis-PEG-peptides of diﬀerent lengths (10, 15 and 20 amino acid residues). For com-
parison, CAF09 was also grafted by inclusion of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy
(PEG)-2000 (DSPE-PEG2000) in the bilayer structure during preparation. Grafting of CAF09 with either type of
PEG resulted in charge shielding, evident from a reduced surface charge. Upon s.c. immunization of mice with
the model antigen ovalbumin (OVA) adjuvanted with PEGylated CAF09, stronger CTL responses were induced as
compared to immunization of mice with unadjuvanted OVA. Biodistribution studies conﬁrmed that grafting of
CAF09 with DSPE-PEG2000 improved the passive drainage of the vaccine to LNs, because a higher dose fraction
was recovered in DCs present in the draining LNs, as compared to the dose fraction detected for non-PEGylated
CAF09. In conclusion, PEGylation of CAF09 may be a useful strategy for the design of an adjuvant, which induces
CTL responses after s.c. and i.m. administration. In the present studies, CAF09 grafted with 10mol% DSPE-
PEG2000 is the most promising of the tested adjuvants, but additional studies are required to further elucidate the
potential of the strategy.
1. Introduction
Guiding the immune system to kill infected or transformed cells
constitutes a promising strategy for preventing so-called diﬃcult-to-
treat infectious diseases caused by obligate intracellular pathogens and
for treating cancer. It is well established that this requires stimulation of
robust antigen-speciﬁc, major histocompatibility complex (MHC)-I-re-
stricted cytotoxic T-lymphocyte (CTL) responses that can mediate
subsequent killing of diseased cells [1]. The subunit vaccine tech-
nology, which exploits peptide or protein antigens consisting of CD8+
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T-cell epitopes, is promising for the design of vaccines that can induce
CTL responses. However, the vast majority of peptide and protein an-
tigens is not capable of inducing T-cell responses upon immunization.
Hence, addition of adjuvants to the vaccines is crucial to stimulate or
enhance induction and control of immune responses [2,3].
A prerequisite for priming of CTL responses is that the vaccine is
targeted to cross-presenting dendritic cells (DCs), which present an-
tigen-derived peptides on MHC-I to CD8+ T cells [4,5]. In mice, two
developmentally related DC subsets have been shown to be capable of
cross-presenting antigens. These include lymph node (LN)-resident
CD8α+ DCs and migratory CD103+ DCs [4,5]. However, it is not fully
understood what the relative importance of each DC subset is for the
induction of CTL responses [6–10]. Cross-presenting DCs express high
levels of Toll-like receptor 3 (TLR3), and activation of TLR3 has been
shown to promote priming of CTL responses [11]. Hence, ligands for
TLR3, e.g., the synthetic double-stranded RNA poly-
inosinic:polycytidylic acid [poly(I:C)], are interesting adjuvants, and
poly(I:C) has been exploited in a number of subunit vaccine formula-
tions to enhance induction of CTL responses [12–14].
We recently demonstrated that strong, antigen-speciﬁc CTL re-
sponses are induced after intraperitoneal (i.p.) immunization with the
liposomal cationic adjuvant formulation (CAF)09 in combination with a
number of disease-relevant antigens [15]. CAF09 is based on di-
methyldioctadecylammonium bromide/monomycoloyl glycerol ana-
logue 1 (DDA/MMG-1) liposomes with poly(I:C) adsorbed to the ca-
tionic DDA headgroups via attractive electrostatic interactions [15].
However, immunization with CAF09-adjuvanted antigens via clinically
relevant administration routes [i.e. subcutaneous (s.c) or intramuscular
(i.m.) immunization] results in weak CTL responses. This is probably a
consequence of an unfavorable biodistribution proﬁle of the vaccine,
which impedes targeting of cross-presenting DCs [16]. Upon injection,
the vaccine has been shown to aggregate due to interaction with in-
terstitial proteins at the site of injection (SOI), eventually preventing
free drainage to the peripheral LNs and passive targeting to LN-resident
CD8α+ DCs [15,16].
Induction of CTL responses after s.c. or i.m. immunization has been
proposed to require passive drainage to the draining LNs (dLNs) via the
lymphatics in order to passively target cross-presenting DCs localized in
the dLNs [17]. Nanoparticles with a size below approximately 200 nm
have been shown to passively drain via the lymphatics to the secondary
lymphoid organs [17–19]. Therefore, aggregation of the vaccine at the
SOI after administration should be avoided, as it may hinder passive
drainage by preventing particle permeation through the endothelial cell
wall of the lymphatics [17].
One strategy for reducing aggregation, and hence depot formation
at the SOI with concomitantly enhanced clearance to the dLNs, is to
surface-graft the liposomes with so-called stealth polymers, e.g., poly-
ethylene glycol (PEG) [20]. PEGylation has been shown to increase the
drainage of liposomes from the SOI upon s.c. immunization [21]. In
addition, PEGylation of the liposomal vaccine adjuvant CAF01 based on
DDA and trehalose 6,6′-dibehenate (TDB) resulted in decreased reten-
tion at the SOI and increased recovery of the liposomes in the dLNs
upon s.c. administration, as compared to non-PEGylated CAF01
[22,23]. This eﬀect was dependent on the PEG grafting density of the
liposomes; liposomes with a grafting density of 25mol% 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-methoxy(PEG)-2000 (DSPE-
PEG2000) were drained to a higher extent than liposomes grafted with
10mol% DSPE-PEG2000 [22,23].
A major drawback of PEGylating vaccines is that the introduction of
a shielding stealth layer on the surface also reduces binding and uptake
of liposomes by antigen-presenting cells (APCs), causing loss of vaccine
eﬃcacy. The uptake level of PEGylated liposomes by APCs has been
shown to be inversely proportional to the PEG grafting density [24,25].
Furthermore, PEGylation of liposomes reduces protein adsorption,
which is inversely proportional to the PEG-chain length and the PEG
grafting density [26,27]. It is well known that the reduced interaction
with proteins like opsonins and lipoproteins results in increased blood
circulation times of liposomes [28]. However, PEGylation may also
interfere with antigen adsorption to adjuvants, as shown recently for
the protein antigen Ag85B-ESAT6, which displayed reduced adsorption
to CAF01 when the adjuvant was PEGylated [22].
Hence, a promising strategy is to design liposomal vaccine ad-
juvants, which are capable of shedding the PEG layer prior to APC in-
teraction. Grafting of liposomes with lipopolymers containing short
lipid anchors, e.g., PEG-ceramides C8 and C14, have been shown to
decrease the dissociation half-lives to less than 1.2 min and ∼1.1 h,
respectively, as compared to a half-life of more than 13 days for dis-
sociation of PEG-ceramide C20 from dioleoylphosphatidylethanolamine
(DOPE):dioleoyldimethylammonium chloride (DODAC) liposomes
[29]. An alternative strategy is to insert degradable linkers between the
lipid anchor and the PEG moiety, which can be cleaved by acid-cata-
lyzed hydrolysis or via proteolysis. Thus, the linkers are cleaved in re-
sponse to an environmental stimulus, e.g., the reduced pH in the en-
dosomes (pH-sensitive linkers), or in the presence of speciﬁc proteolytic
enzymes (peptide-based linkers) [30].
The purpose of this study was to investigate the eﬀect of PEGylation
on the ability of CAF09 to induce antigen-speciﬁc CTL responses after
s.c. administration using net anionic ovalbumin (OVA) as model an-
tigen. We compared two diﬀerent PEGylation strategies. First, we tested
a new approach for post-preparation surface grafting with PEG moi-
eties. For this, a novel type of PEG-peptides, composed of an anionic
peptide backbone (GDGDY repeats) and end-conjugated to one or two
PEG1000 moieties were used (Table 1). The rationale for this design was
concomitant post-adsorption of anionic PEG-peptide and OVA to the net
positively charged cationic liposomes via attractive electrostatic inter-
actions. Our hypothesis was that surface grafting of CAF09 with such
PEG-peptides would reduce depot formation upon s.c. injection and
enhance vaccine clearance to the dLNs. We also envisaged that the PEG-
peptide may subsequently desorb from the antigen-coated liposomes at
a rate depending on: (i) the length of the anionic peptide chain, and (ii)
the grafting density. This could potentially enhance vaccine interaction
with APCs in the dLNs. The second strategy included conventional
PEGylation of CAF09 by inclusion of DSPE-PEG2000 in the liposomal
bilayer structure during preparation, followed by OVA adsorption to the
PEGylated CAF09.
Table 1
Array of PEG-peptides. These analogues include mono- and bis-PEG-peptides.
Abbreviation Class of PEG-peptide Peptide length Peptide sequence
aa-10-monoPEG1000 MonoPEG-peptide 10 GDGDY GDGDY
aa-15-monoPEG1000 15 GDGDY GDGDY GDGDY
aa-20-monoPEG1000 20 GDGDY GDGDY GDGDY GDGDY
aa-10-bisPEG1000 BisPEG-peptide 10 GDGDY GDGDY
aa-15-bisPEG1000 15 GDGDY GDGDY GDGDY
aa-20-bisPEG1000 20 GDGDY GDGDY GDGDY GDGDY
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2. Materials and methods
2.1. Materials
DDA and MMG-1 were purchased from NCK A/S (Farum, Denmark),
while DSPE-PEG2000 was acquired from Avanti Polar Lipids (Alabaster,
AL, USA). γ-Irradiated poly(I:C) was obtained from Sigma-Aldrich (St.
Louis, MO, USA), and endograde OVA was from Hyglos GmbH
(Bernried am Starnberger See, Germany). All other chemicals were used
at analytical grade and purchased from commercial suppliers. Tris
buﬀer (10mM, pH 7.4) was used throughout the studies owing to the
optimal stability of CAF01 in this buﬀer [31].
2.2. Synthesis of PEG-peptides
An array of PEG-peptides was designed to study the inﬂuence of
peptide length [10, 15, and 20 amino acid (aa) residues, respectively]
and degree of PEGylation (mono- versus bis-PEGylation) on the ad-
sorption of the PEG-peptides to CAF09 (Table 1). The peptides were
composed of blocks of ﬁve aa (GDGDY) repeated two, three and four
times, respectively, and they were synthesized at> 95% purity by
Genecust (Ellange, Luxembourg). The conjugates were synthesized by
N-terminal PEGylation, as described elsewhere [32]. Brieﬂy, 50 nmol of
peptide was dissolved in acetate buﬀer (pH 5, NaOAc·H2O; 17ml), and
subsequently 5–6 equivalents of PEG-aldehyde (1101.31 g/mol, Iris
Biotech GmbH, Marktredwitz, Germany) were added to the solution,
followed by 50 equivalents of NaCNBH3 in 3ml acetate buﬀer. For the
10 aa peptide, the mixture was stirred for approximately 3 h, while the
15 aa peptide mixture was stirred for approximately 24 h. Then 17
equivalents of NaCNBH3 were added, and the mixture was stirred for an
additional 2 h. Analytical HPLC (see below) of the resulting mixture
indicated peaks corresponding to both mono- and bis-PEG-peptides
(results not shown).
Analytical HPLC of the PEG-peptides was performed using a Luna
2.5 µm C18(2) High Speed Technology (HST) column (3.0× 100mm)
with a ﬂow of 0.5ml/min, or a Luna 3 µm C18(2) column
(4.6×150mm) (both Phenomenex, Torrance, CA, USA) at a ﬂow rate
of 0.8 ml/min. Peaks were UV-detected at 220 nm. Binary mixtures of
eluent A [5% (v/v) MeCN in H2O with 0.1% (v/v) triﬂuoroacetic acid
(TFA)] and eluent B [95% MeCN in H2O with 0.1% (v/v) TFA] were
used. For the Luna 2.5 µm column, the fraction of eluent B to eluent A
was increased from 10 to 60% (v/v) in 10min, while for the Luna 3 µm
column, the fraction of eluent B to eluent A was increased from 10 to
60% (v/v) in 30min. The retention times (RT) of the PEG-peptides
were: 10aa-monoPEG RT=6.02min (Luna 2.5 µm), RT=22.13min
(Luna 3 µm); 10aa-bisPEG RT=7.46min (Luna 2.5 µm),
RT=26.25min (Luna 3 µm); 15aa-monoPEG RT=5.96min (Luna
2.5 µm), RT=22.52min (Luna 3 µm); 15aa-bisPEG RT=7.31min
(Luna 2.5 µm), RT= 26.81min (Luna 3 µm). Puriﬁcation was per-
formed by preparative HPLC using a Luna 5 µm C18(2) column
(30× 250mm) at a ﬂow rate of 40ml/min, and increasing the fraction
of eluent B from 10 to 45% (v/v) in 20min. All peptides were> 95%
pure.
2.3. Preparation of liposomes
Liposomes were prepared by dissolving weighed amounts of lipids
in 99% (v/v) EtOH. In a glass vial, DDA, MMG-1, DSPE-PEG2000 and the
ﬂuorescent label 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO,
Life Technologies, Nærum, Denmark) were mixed and dried under a
stream of N2 for 2 h, followed by air-drying overnight. The dry lipid
ﬁlms were rehydrated in Tris buﬀer by high-shear mixing (HSM) using
a Heidolph Silent Crusher equipped with a 6F shearing tool (Heidolph
Instruments GmbH, Schwabach, Germany) at 60 °C and 26,000 rpm for
15min. The poly(I:C) was added continuously during HSM using a
peristaltic pump (Pharmacia Biotech, Stockholm, Sweden) over 30min.
The concentrations of the components in the resulting dispersions were
2.5/0.5/0.5 mg/ml DDA/MMG-1/poly(I:C), eventually supplemented
with 0.07–1.51mg/ml DSPE-PEG2000 (0.5–10mol%) and/or 20 µg/ml
DiO, in a dose volume of 100 µl. To prepare liposomes coated with PEG-
peptides, CAF09 was added to PEG-peptides diluted to diﬀerent con-
centrations in Tris buﬀer (1:1, v/v), and then formulations were mixed
by continuous rotation for 30min to ensure maximal adsorption of the
PEG-peptides to the liposomes. The PEG-peptides (1–10mol%) diluted
in Tris buﬀer were added to CAF09 at 1:1 (v/v) (Suppl. Table S1).
2.4. Physicochemical characterization of liposomes
The average hydrodynamic diameter (z-average) of the liposomes
and the polydispersity index (PDI) were measured by dynamic light
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments Ltd,
Worcestershire, UK) equipped with a 633 nm laser and 173° detection
optics. The samples were diluted 10 times in Tris buﬀer, and the values
of water were used for viscosity and refractive indexes. The zeta-po-
tentials were measured by diluting the liposomes 100 times in milliQ
water. Zetasizer Software v7.11 (Malvern Instruments Ltd) was used for
acquisition and analysis of data. Adsorption of OVA to CAF09-PEG-lipid
was evaluated at grafting densities of 0, 1, 2.5, 5, and 10mol% DSPE-
PEG2000 and ﬁnal OVA concentrations in the range of 0.05–1.5 mg/ml.
The liposome dispersions and OVA were mixed for 30min to ensure
adsorption prior to ultracentrifugation at 137,500g for 30min. at 4 °C.
The amount of non-adsorbed OVA in the supernatant was determined
by using the bicinchoninic acid (BCA) assay (Pierce BCA protein assay
kit, ThermoFisher Scientiﬁc Inc. Waltham, MA, USA). The adsorption of
OVA to CAF09 grafted with 10mol% aa15-bisPEG1000 was evaluated in
Tris buﬀer at pH 7.4 by mixing 10.0 µl 2mg/ml AlexaFluor (AF) 647-
conjugated OVA (ThermoFisher Scientiﬁc Inc.) with 15.4 µl 10mg/ml
PEG-peptide and 100 µl CAF09 in a total volume of 200 µl in 1.5ml low
adsorption Eppendorf tubes. The mixture was left to equilibrate at room
temperature (rt) for approximately 10min and ultracentrifuged at
137,500g for 30min. at 4 °C. The concentration of non-adsorbed OVA in
the supernatant was determined by ﬂuorescence spectroscopy using a
FluoSTAR Optima (BMG Labtech, Ortenberg, Germany). The percen-
tage of liposome-adsorbed protein was calculated by subtracting the
amount of protein remaining in solution from the amount of protein
initially added to the liposome dispersion.
2.5. Biodistribution studies
The animal experiments were conducted in accordance with the
national Danish guidelines for animal experiments, as approved by the
Danish Council for Animal Experiments and in accordance with EU
directive 2010/63/EU for animal experiments. All eﬀorts were made to
ensure maximum comfort for the animals, and they were allowed free
access to food and water. The biodistribution of the antigen and the
adjuvant, respectively, and the inﬂux of immune cells to the SOI and the
dLNs upon i.m. immunization were compared for the vaccines ad-
juvanted with non-PEGylated and PEGylated CAF09, respectively. The
i.m. administration route was applied, as it enabled removal of the SOI
for analysis. The vaccines adjuvanted with non-PEGylated CAF09 and
CAF09 grafted with 10mol% DSPE-PEG2000, respectively, were pre-
pared by mixing the adjuvant and the model antigen OVA (10 µg/dose)
in Tris buﬀer for 30min with intermittent vortexing. For the formula-
tions with 20mol% aa15-bisPEG1000, OVA and the PEG-peptide were
diluted in Tris buﬀer prior to addition of CAF09, and the three com-
ponents were mixed for 30min. Female, C57BL/6 mice aged
8–10weeks were immunized i.m. in both quadriceps with vaccines
prepared as described above using the DiO-containing adjuvant and
AF647-conjugated OVA (15 µg/dose) in a dose volume of 50 µl/muscle.
The mice were euthanized 3, 24, 48, 96 and 168 h after immunization,
respectively, and the dLNs and quadriceps were isolated.
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2.6. Immunization studies
The immune responses to the vaccines OVA/CAF09 and OVA/
CAF09 with 10mol% aa15-bisPEG1000 (OVA/CAF09-PEG-peptide) and
10mol% DSPE-PEG2000 (OVA/CAF09-PEG-lipid), respectively, were
evaluated by immunization of female, 7–9-week-old C57BL/6 mice
(Harlan, Horst, The Netherlands). The mice were immunized two times
s.c. at the base of the tail with a two-week interval, and the inguinal LNs
(ILN), the spleen and the blood were harvested one week after the ﬁnal
immunization. The s.c. administration route was chosen for the im-
munity studies, because it inﬂicts less pain to the the mice, as compared
to i.m. immunization.
2.7. Preparation of organs
Single cell suspensions of the LNs and the spleens were prepared by
passage of the organs through a nylon mesh cell strainer, followed by
washing in phosphate-buﬀered saline (PBS) or RPMI 1640 (Gibco
Invitrogen, Carlsbad, CA, USA) or FACS-buﬀer [PBS with 10% fetal calf
serum (FCS)]. The muscles were treated with the enzymes A, D and P
from the Skeletal Muscle Dissociation Kit (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) according to the manufacturer’s in-
structions, and 200 µl of the supernatants were removed prior to
washing, which was performed as described above. Single cell sus-
pensions used for re-stimulation studies were resuspended in RPMI
1640 supplemented with 10% (v/v) heat-inactivated FCS, 5×10−6 M
β-mercaptoethanol, 1% (v/v) penicillin–streptomycin, 1% (v/v) sodium
pyruvate, 1 mM L-glutamine, and 10mM HEPES. The blood was har-
vested in EDTA-tubes and loaded onto Lympholyte (Cedarlane,
Burlington, Canada) followed by centrifugation at 900g for 20min. The
lymphocytes were harvested and treated as described above.
2.8. Intracellular and surface ﬂow cytometry
For the biodistribution studies, immune cells in the muscle tissue
and the dLNs were identiﬁed by surface staining the cells with anti-
Ly6G:PE (1A8, BD Biosciences, San Jose, NJ, USA), anti-CD11b:PerCP-
Cy5.5 (M1/70, BD Biosciences), anti-F4/80:PE-Cy7 (BM8, eBioscience,
San Diego, CA, USA), anti-Ly6C:APC-Cy7 (HK1.4, Biolegend, San Diego,
CA, USA), anti-CD11c:BV421 (HL3, BD Biosciences), anti-CD86:BV510
(GL1, BD Biosciences), and anti-CD19:BV786 (1D3, BD Biosciences).
Cellular subsets were identiﬁed by the presence or absence of surface
markers, essentially as described previously [33] (Suppl. Fig. S1 and
S2). The data were acquired by using a BD Fortessa or a BD Canto ﬂow
cytometer (BD Biosciences), and they were analyzed by using the
FlowJo vX software (Tree Star, Ashland, OR, USA).
The frequency of OVA-speciﬁc CD8+ T cells was determined by
SIINFEKL-pentamer ﬂow cytometry. A number of 106 cells/well was
stained with PE-labelled H-2 Kb-SIINFEKL (ProImmune, Oxford, UK) for
15min at rt, followed by treatment with Fc-block (anti-mouse CD16/
CD32, BD Biosciences) for 10min and staining with anti-CD62L:FITC
(MEL-14, BD Biosciences), anti-CD8:PerCP-Cy5.5 (53–6.7, eBioscience),
anti-CD19:PE-Cy7 (1D3, BD Biosciences), anti-CD44:APC (IM7, BD
Biosciences), and anti-CD4:eFluor780 (RM4-5, eBioscience), respec-
tively, for 30min.
2.9. Meso scale discovery (MSD) assay
Induction of pro-inﬂammatory cytokines and chemokines in the
muscles following immunization were evaluated by MSD (Meso Scale
Diagnostics LLC, Rockville, MD, USA). A seven-spot pro-inﬂammatory
plate [Interferon (IFN)-γ, IL-1β, IL-6, keratinocyte chemoattractant/
human growth-regulated oncogene (KC/GRO), IL-10, IL-12p70, and
tumor necrosis factor (TNF)-α] and a separate monocyte chemoat-
tractant protein (MCP)-1 plate were used. A volume of 25 µl undiluted
muscle supernatant was pipetted into each well and diluted with 25 µl
Diluent 41, followed by incubation for 2 h on a shaking table at rt. The
plates were washed with PBS supplemented with 0.05% (v/v) Tween
20, followed by incubation with detection antibodies for 2 h on a
shaking table at rt. Finally, read buﬀer was added to the plates, and
they were read using a Meso Sector S600 with Discovery Workbench
4.0. MSD software (Meso Scale Diagnostics LLC).
2.10. Statistical analysis
One-way or two-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparisons test were used to analyze the diﬀerence
between the individual groups using GraphPad Prism version 6.05 for
Windows (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. Pegylation of CAF09 reduces the particle size and zeta-potential
CAF09 was PEGylated using 2.5, 5.0, or 10mol% of DSPE-PEG2000,
and the average hydrodynamic particle diameter and PDI were mea-
sured. At 5 and 10mol% DSPE-PEG2000, the z-average was signiﬁcantly
smaller than the z-average of the non-PEGylated CAF09, while the PDI
was not signiﬁcantly aﬀected (Fig. 1a). As expected, the zeta-potential
was reduced as a function of the PEG grafting density, resulting in near-
neutral zeta-potential at PEG grafting densities of 5 and 10mol%
(Fig. 1b).
The degree of adsorption of the model antigen OVA to PEGylated
CAF09 was determined at diﬀerent DSPE-PEG2000 grafting densities
(Fig. 1c). For grafting densities up to 5mol%, OVA was 100% adsorbed
to CAF09 at concentrations below 0.2 mg/ml, which covers the con-
centration range usually used in vaccines (0.05–0.075mg/ml). At in-
creasing OVA concentration, the amount of OVA adsorbed to the lipo-
somes decreased as a function of the PEG-grafting density. However, it
was diﬃcult to sediment CAF09 with 10mol% DSPE-PEG2000 during
ultracentrifugation, especially at low OVA concentrations, maybe as a
combined result of steric repulsion between the PEG chains. The mor-
phology of CAF09 grafted with 10mol% DSPE-PEG2000 was imaged
using cryo-transmission electron microscopy (cryoTEM). The observed
liposomes displayed varying degrees of lamellarity and sizes (Suppl.
Fig. S3), as shown previously for non-PEGylated CAF09 [16].
In addition, CAF09 was PEGylated using the PEG-peptides of dif-
ferent peptide chain lengths (10, 15 and 20 aa), which were mono- and
bis-PEGylated, respectively (Table 1). The PEG-peptides and CAF09
were mixed at diﬀerent molar ratios. The mixture was incubated for
30min with intermittent agitation to allow complete adsorption of the
anionic PEG-peptides to the cationic liposomal surface prior to mea-
suring the z-average and the zeta-potential of the formulations. As ex-
pected, the zeta-potentials decreased at increasing molar ratios of PEG-
peptides. At 10mol%, the zeta-potentials depended on the length of the
peptide; surface grafting with 10mol% 10 aa PEG-peptide resulted in a
zeta-potential of approximately 20–30mV, whereas coating with the 15
aa PEG-peptide resulted in a near neutral zeta-potential, and CAF09
grafted with the 20 aa PEG-peptides displayed a zeta-potential of ap-
proximately −20mV (Fig. 1d). The zeta-potential was not dependent
on the degree of PEGylation (mono- versus bis-PEGylation) in the ex-
amined concentration range. The eﬀect on zeta-potential suggests that
the PEG-peptides are capable of shielding the cationic surface charge.
When the 20 aa peptide was used at high molar ratios, the negative
charge of the peptides might exceed the cationic charge of the lipo-
somes. The z-average of the liposomes was largely inﬂuenced by the
molar ratio, as PEGylation at the lowest molar ratios tested resulted in
aggregation of the liposomes, which was not evident at higher molar
ratios. It is likely that the presence of the PEG chains prevents ag-
gregation at the higher molar ratios tested, while bridging attractive
electrostatic interactions exist between the peptide and liposomes at the
lower molar ratios tested, eventually resulting in aggregation (Fig. 1e).
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The liposome dispersions grafted with PEG-peptides were relatively
monodisperse displaying PDI values below 0.2, except for CAF09
grafted with aa20-monoPEG1000, which had PDIs of approximately 0.35
(Suppl. Fig. S4). The adsorption of the model antigen OVA labelled with
AF647 was only determined for the adjuvant tested in the subsequent
immunogenicity studies (CAF09 grafted with 10mol% aa15-
bisPEG1000). The adsorption of OVA to CAF09 grafted with aa15-
bisPEG1000 was approximately 59% (Fig. 1f). In contrast 100% OVA
was adsorbed to non-PEGylated CAF09. The reduction in OVA ad-
sorption to CAF09 after grafting with 10mol% aa15-bisPEG1000 may be
due to attractive electrostatic interactions between the cationic DDA
headgroups and the PEG-peptide at this concentration, evident from the
neutral zeta-potential (Fig. 1d). Hence, shielding of the cationic surface
charge by grafting with PEG-peptide may reduce the available cationic
surface charge responsible for adsorption of negatively charged OVA,
which has an isoelectric point of 4.5.
Fig. 1. Physicochemical characterization of PEGylated CAF09. (a) z-average and PDI of CAF09-PEG-lipid. Data represent mean values ± SEM, n= 3–8. **p≤ 0.01,
as compared to CAF09. (b) Zeta-potential of CAF09 grafted with DSPE-PEG2000. Data represent mean values ± SEM, n= 3–5. **p≤ 0.01 and ****p≤ 0.0001, as
compared to CAF09. (c) Relative adsorption in percent of OVA to CAF09 grafted with DSPE-PEG2000. Data represent mean values ± SEM, n= 3. (d) Zeta-potential
and (e) z-average of CAF09 PEGylated with diﬀerent PEG-peptides, n= 2. (f) Adsorption of AF647-conjugated OVA to non-PEGylated CAF09 and CAF09 grafted with
10mol% aa-15-bisPEG1000, n=2.
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3.2. Biodistribution of vaccines following i.m. immunization
Mice were immunized i.m. in the quadriceps with AF647-con-
jugated OVA adjuvanted with DiO-labelled formulations (i) CAF09, (ii)
CAF09 with 20mol% PEG-peptide (aa15-bisPEG1000, referred to as
CAF09-PEG-peptide) and (iii) CAF09 with 10mol% PEG-lipid (DSPE-
PEG2000, referred to as CAF09-PEG-lipid), respectively. The choice of
the speciﬁc molar PEG grafting densities was based on the
Fig. 2. Cellular composition in the quadriceps following i.m. immunization with unadjuvanted OVA, OVA adjuvanted with non-PEGylated CAF09, CAF09-PEG-
peptide (20mol% aa-15-bisPEG1000) and CAF09-PEG-lipid (10mol% DSPE-PEG2000). (a) Total inﬂux of cells into the quadriceps. (b) Number of neutrophils in
quadriceps per g muscle. (c) The frequency of vaccine+ neutrophils. (d) Number of inﬂammatory monocytes in quadriceps per g muscle. (e) The frequency of
vaccine+ inﬂammatory monocytes. (f) The number of cDCs in the quadriceps. (g) The number of vaccine+ cDCs in the quadriceps. Data represent mean ± SEM,
n= 2 (naïve mice and mice immunized with unadjuvanted OVA) and 4 (mice immunized with adjuvanted OVA). 2-way ANOVA followed by Tukey’s multiple
comparisons test comparing the groups; CAF09, CAF09+PEG-peptide 20mol% and CAF09+PEG-lipid 10mol%, *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001,
****p≤ 0.0001. Signiﬁcance markers are colored according to involved groups.
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physicochemical characteristics of the resulting liposome dispersions:
CAF09 grafted with 20mol% PEG-peptide displayed particle sizes and
zeta-potentials (219 nm and 7mV, respectively) comparable to those of
CAF09 grafted with 10mol% PEG-peptide. Hence, grafting densities
between 0 and 10mol% were investigated further. The number of im-
mune cells present in the quadriceps increased signiﬁcantly within the
ﬁrst 48 h after immunization, as compared to the number of cells for
naïve mice (Fig. 2a), whereas there was no signiﬁcant change in the
number of immune cells in the dLNs throughout the study (results not
shown). The identity of the immune cells and their relative degree of
vaccine association at the SOI and in the dLNs were evaluated by ﬂow
cytometry (Suppl. Fig. S1 and S2).
In the quadriceps, the OVA/CAF09-PEG-peptide vaccine caused the
largest inﬂux of neutrophils (Ly6G+) 24 h after immunization, while
the OVA/CAF09-PEG-lipid vaccine induced a slightly larger inﬂux of
inﬂammatory monocytes (F4/80+Ly6C+) (Fig. 2b/c). Interestingly, the
frequency of vaccine-positive neutrophils was lower for the group im-
munized with the OVA/CAF09-PEG-lipid vaccine at late time points, as
compared to the other vaccines (Fig. 2d). In contrast, the CAF09-PEG-
lipid vaccine was associated with inﬂammatory monocytes to a slightly
higher extent than the other vaccines (Fig. 2e). Furthermore, un-
adjuvanted OVA was only associated with inﬂammatory monocytes and
not with neutrophils (Fig. 2e).
Inﬂux of conventional DCs (cDCs; CD11c+, CD11b+) was detectable
at the SOI 48 h after administration, and was thus delayed, as compared
to the inﬂux of neutrophils and inﬂammatory monocytes to the SOI
(Fig. 2f). Immunization with the OVA/CAF09-PEG-lipid vaccine caused
a higher inﬂux of cDCs into the quadriceps and resulted in a sig-
niﬁcantly higher number of vaccine+ cDCs at the late time points, as
compared to immunization with the other adjuvants (Fig. 2g).
3.3. Immunization with CAF09-PEG-peptide induces a pro-inﬂammatory
environment at the SOI
The cytokine responses at the SOI after immunization with OVA/
CAF09, OVA/CAF09-PEG-lipid, and OVA/CAF09-PEG-peptide were
evaluated by MSD (Fig. 3). The cytokines and chemokines IFN-γ, IL-1β,
KC/GRO, MCP-1 and TNF-α were all induced by the adjuvants, while
there was no signiﬁcant induction of IL-10, IL-12p70 and IL-6. For KC/
GRO, induction was observed 3 h after immunization, which suggests
that a minor dose fraction of the vaccine is phagocytosed at that time
point (results not shown). The cytokine levels were increased at 24 h
p.i. for the immunized groups, and the OVA/CAF09-PEG-peptide vac-
cine induced signiﬁcantly higher IFN-γ and IL-1β responses than OVA/
CAF09 (only IFN-γ, Fig. 3a) and OVA/CAF09-PEG-lipid (Fig. 3b), and
induced higher levels of TNF-α, MCP-1 and KC/GRO, than the OVA/
CAF09 vaccine (Fig. 3c–e). Hence, the OVA/CAF09-PEG-peptide vac-
cine appears to have a greater pro-inﬂammatory potential than the
other vaccines, possibly due to desorption of poly(I:C) from the vaccine
after administration.
3.4. CAF09 PEGylated with DSPE-PEG2000 associates with cDCs in the
dLNs
The vaccine recovery in the dLNs was measured as the frequency of
OVA+ and DiO+ single-positive lymphocytes (Fig. 4a/b). The fre-
quency of OVA+DiO+ double-positive cells was negligible (Suppl. Fig.
S2), hence this cell population was not considered further. Immuniza-
tion with OVA adjuvanted with CAF09-PEG-lipid resulted in sig-
niﬁcantly larger association of OVA with cells 24 p.i., as compared to
the other groups, whereas immunization with OVA adjuvanted with
CAF09-PEG-peptide resulted in less OVA association with the cells
(Fig. 4a). The presence of OVA+ cells might indicate that a fraction of
the antigen is desorbed from the PEGylated adjuvants and drains pas-
sively to the dLNs.
Only immunization with OVA adjuvanted with CAF09-PEG-lipid
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Fig. 3. Inﬂammatory cytokines in the quadriceps, as measured by MSD, 24 h
following i.m. immunization with unadjuvanted OVA, OVA adjuvanted with
non-PEGylated CAF09, CAF09-PEG-peptide (20mol% aa-15-bisPEG1000) and
CAF09-PEG-lipid (10mol% DSPE-PEG2000). (a) INF-γ, (b) IL-β, (c) KC/GRO, (d)
MCP-1, and (e) TNF-α. **p≤ 0.01 and *p≤ 0.05 CAF09-PEG-peptide as com-
pared to the other groups. Data represent mean ± SEM, n= 2 (naïve mice and
mice immunized with unadjuvanted OVA) and 4 (mice immunized with ad-
juvanted OVA).
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resulted in signiﬁcant frequencies of DiO+ cells, indicating that the
vaccine is either transported or passively drained to the dLNs (Fig. 4b).
None of the other adjuvants were detected in the dLNs above baseline
level, however, they may have been degraded prior to entry into the
dLNs. Similarly, the absence of OVA in the DiO+ cells might indicate
that the antigen is degraded.
After 48 h, the CAF09-PEG-lipid vaccine (either OVA+ or DiO+)
was associated with cDCs and CD11blow DCs in the dLNs to a sig-
niﬁcantly higher extent than the other vaccines (Fig. 4c/d), whereas
there was little association with B cells (Fig. 4e). In combination, these
results indicate that CAF09-PEG-lipid is drained to the dLNs and as-
sociates with the cDCs much more eﬃciently than CAF09 and CAF09-
PEG-peptide.
3.5. CAF09 PEGylated with DSPE-PEG2000 and PEG-peptide, respectively,
induces antigen-speciﬁc CD8+ T-cell responses
The immunogenicity of PEGylated CAF09 was evaluated in C57BL/
6 mice with the model antigen OVA. CAF09 was PEGylated with 10mol
% PEG-peptide (aa15-bisPEG1000, CAF09-PEG-peptide) and 10mol%
PEG-lipid (DSPE-PEG2000, CAF09-PEG-lipid), which were administered
s.c. two times with a 2-week interval.
The levels of antigen-speciﬁc CD8+ T cells in the blood and dLNs of
immunized mice were evaluated by staining with the speciﬁc CD8
epitope SIINFEKL-loaded MHC-I-pentamer and relevant ﬂuorescent
antibodies followed by ﬂow cytometry (Fig. 5a). In the blood, mice
immunized with OVA/CAF09-PEG-peptide and OVA/CAF09-PEG-lipid
displayed signiﬁcantly higher levels of antigen-speciﬁc CD8+ T cells as
compared to the naïve and OVA-immunized mice (Fig. 5b). The levels
of antigen-speciﬁc CD8+ T cells in the mice immunized with OVA/
CAF09 were comparable to the levels found in previous immunization
studies [16]. Furthermore, the levels of antigen-speciﬁc CD8+ T cells in
the dLNs were signiﬁcantly higher in the mice immunized with CAF09-
PEG-lipid as compared to the other groups in the study (Fig. 5c).
4. Discussion
PEGylation of cationic adjuvants is an attractive approach for re-
ducing depot formation at the SOI and increasing passive drainage to
the dLNs. PEGylation of CAF09 with DSPE-PEG2000 resulted in
Fig. 4. Recovery of vaccine in the dLNs as measured by ﬂow cytometry, following i.m. immunization with unadjuvanted OVA, OVA adjuvanted with non-PEGylated
CAF09, CAF09-PEG-peptide (20mol% aa-15-bisPEG1000) and CAF09-PEG-lipid (10mol% DSPE-PEG2000). (a) Frequency of OVA+ cells. ***p≤ 0.001 CAF09-PEG-
lipid as compared to the other groups, *p≤ 0.05 CAF09-PEG-peptide as compared to CAF09. (b) Frequency of DiO+ cells. ****p≤ 0.0001 and **p≤ 0.001 CAF09-
PEG-lipid as compared to the other groups. (c) Frequency of vaccine+ cDCs and (d) frequency of vaccine+ CD11blow DCs of cell population 48 h after i.m. im-
munization. ****p≤ 0.0001 and *p≤ 0.05 CAF09-PEG-lipid as compared to the other groups. (e) Frequency of vaccine+ B cells of cell population 48 h after i.m.
immunization. *p≤ 0.05 CAF09-PEG-peptide as compared to unadjuvanted OVA. Data represent mean ± SEM, n=2 (naïve mice and mice immunized with
unadjuvanted OVA) and 4 (mice immunized with adjuvanted OVA).
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relatively small liposomes (approx. 130 nm for CAF09 with 10mol%
DSPE-PEG2000), and the apparent surface charge was reduced as a
function of the PEG grafting density. The zeta-potentials of CAF09
mixed with PEG-peptides decreased as a function of the length of the
peptide and concentration of the PEG-peptide. The zeta-potentials ap-
peared to start forming a plateau for CAF09 with the aa-15 and aa-20
PEG-peptides at higher concentrations, which was not observed for the
aa-10 PEG-peptide. The mechanisms of shielding of the liposomal sur-
face are apparently very diﬀerent for the two PEGylation strategies.
Hence, when using a lipid-anchor for PEGylation, the surface charge is
shielded via the formation of a stealth PEG layer on the particle surface
[34]. The PEG-moieties adopt diﬀerent conformations, depending on
the grafting density; at a low density (< 5 mol%) the PEG moieties are
expected to adopt a mushroom-like conformation [20,34]. Increasing
the grafting density induces a change to a brush-border conformation of
the PEG moieties due to steric repulsion. At higher grafting densities
(above approx. 10mol%), the liposomes become destabilized due to
increased steric repulsion [20,34]. Furthermore, the reduced particle
size observed at increasing mol% of DSPE-PEG2000 is likely a result of
colloidal stabilization, which prevents aggregation during liposome
preparation due to steric repulsion between the PEG moieties.
Despite PEGylation with DSPE-PEG2000, poly(I:C) and OVA are ad-
sorbed to CAF09 to a certain extent. On the other hand, PEGylation
with PEG-peptides involves the direct attractive electrostatic interac-
tion between the DDA headgroups and the negatively charged peptides,
and this process is in direct competition with the adsorption of poly(I:C)
and OVA (that the peptides might also interact with). However, this
opens the possibility that the PEG-peptides may desorb in vivo after
immunization, perhaps due to dissociation or competition with inter-
stitial proteins. For this strategy to be successful, the kinetics of deso-
rption is key. Hence, the desorption kinetics of the injected liposomes
should be optimized to allow diﬀusion of the liposomes into the lym-
phatics before dissociation of the PEG-peptides takes place.
While all the vaccine formulations caused a signiﬁcant inﬂux of
immune cells into the SOI, the adjuvants attracted diﬀerent types of
cells, as the OVA/CAF09-PEG-peptide attracted more neutrophils than
the other adjuvants, whereas the OVA/CAF09-PEG-lipid attracted more
inﬂammatory monocytes. Interestingly, neutrophils and inﬂammatory
monocytes took up the vaccine particles to the same extent, indicating
that the adjuvants do not target speciﬁc immune cell subsets. The OVA/
CAF09-PEG-peptide induced higher levels of IFN-γ and IL-1β, which
was in accordance with the inﬂux of neutrophils and inﬂammatory
monocytes peaking earlier and at higher levels for this adjuvant, as
compared to the other adjuvants. Furthermore, KC/GRO was induced
already after 3 h, which is in accordance with the early peak of neu-
trophil inﬂux, as compared to inﬂammatory monocyte inﬂux.
Fig. 5. Immune responses following s.c. immunization with unadjuvanted OVA, OVA adjuvanted with non-PEGylated CAF09, CAF09-PEG-peptide (10mol% aa-15-
bisPEG1000) and CAF09-PEG-lipid (10mol% DSPE-PEG2000) as evaluated one week after the ﬁnal of two immunizations. (a) Plots of antigen-speciﬁc CD8+ T cells in
the blood of diﬀerent immunization groups. Antigen-speciﬁc CD8+ T cells in (b) the blood and (c) the dLNs were measured by ﬂow cytometry identifying
CD44+,CD8+ T cells binding ﬂuorescently labeled SIINFEKL-MHC-I complexes. Data represent results from two identical studies (black circles and red triangles,
respectively), mean ± SEM, n= 8. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 and ****p≤ 0.0001, one-way ANOVA followed by Tukey’s post test.
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The inﬂux of DCs into the SOI was maximal and reached a plateau at
48 h for the OVA/CAF09-PEG-lipid vaccine, whereas the inﬂux peaked
at 96 h for the OVA/CAF09 vaccine and the OVA/CAF09-PEG-peptide
vaccine. Simultaneously, the frequency of vaccine+ cDCs was highest
for mice vaccinated with the OVA/CAF09-PEG-lipid and lowest for the
mice vaccinated with OVA/CAF09-PEG-peptide. Interestingly, the
OVA/CAF09-PEG-lipid vaccine displayed the highest frequency of as-
sociation with cDCs, despite the lipid-anchored PEG-moieties. This
adjuvant might be believed to have the lowest capability of interacting
with APCs due to the lipid anchor of the PEG-moities that has been
shown to play a role in preventing cellular absorption of PEGylated
liposomes [24,25].
The dLNs from mice immunized with OVA/CAF09-PEG-lipid dis-
played signiﬁcantly higher frequencies of association with total lym-
phocytes and cDCs in particular, as compared to those from mice im-
munized with OVA/CAF09 and OVA/CAF09-PEG-peptide.
Interestingly, only single-positive (i.e., either OVA+ or DiO+) immune
cells were observed in the dLNs. This is in contrast to the SOI where the
vaccine+ cells were almost exclusively double-positive. Possibly, this is
because the components of the vaccine drain separately from the SOI,
or that the ﬂuorescent labels are degraded at diﬀerent rates in the cells.
From this study, it is not possible to deduce, whether the vaccine+ cells
in the dLNs had migrated from the SOI, or if the vaccine particles
drained passively to the dLNs prior to phagocytosis by APCs. The ki-
netics of vaccine association with lymphocytes in the dLNs indicate
migration by APCs from the SOI, as other studies have shown that
passive drainage of CAF09 takes place within 6 h following i.p. im-
munization [16]. Despite the large inﬂux of neutrophils taking up
vaccine into the SOI, no vaccine+ neutrophils were observed in the
dLNs, indicating that the neutrophils at the SOI do not migrate to the
dLNs, and hence are not involved in the lymphatic targeting.
The hypothesis of the study was that PEGylation of CAF09 reduces
depot formation at the SOI and enhances the drainage to the dLNs. It
was shown that grafting of CAF09 with DSPE-PEG2000 resulted in
drainage of a larger dose fraction to the dLNs, as compared to non-
PEGylated CAF09. However, it was not possible in the present study to
conﬁrm that this was indeed due to a reduction of depot formation at
the SOI. Hence, the results rather indicate that a vaccine depot will
form with these adjuvants, but drainage to the dLNs can be achieved by
speciﬁcally designing the adjuvants for the purpose, e.g. by PEGylation.
5. Conclusion
Grafting of CAF09 with PEG-lipid and PEG-peptide showed a ten-
dency, though statistically not signiﬁcant, toward induction of stronger
CD8+ T-cell responses in the blood upon s.c. immunization than found
for non-PEGylated CAF09. CAF09-PEG-lipid induced signiﬁcantly
higher CD8+ T-cell responses in the dLNs as compared to the other
adjuvants. The biodistribution studies correlated with these ﬁndings, as
signiﬁcantly larger numbers of cDCs in the dLNs were vaccine+ fol-
lowing i.m. immunization with OVA/CAF09-PEG-lipid, as compared to
OVA/CAF09. From the present studies, CAF09 grafted with 10mol%
DSPE-PEG2000 appears as the most promising of the tested adjuvants
because it displays drainage of the largest dose fraction to the dLNs and
induces the strongest local immune response. I.m. immunization with
OVA/CAF09-PEG-peptides resulted in increased stimulation of pro-in-
ﬂammatory cytokines, which resulted in an increased inﬂux of neu-
trophils into the SOI, as compared to that observed when immunizing
with OVA/CAF09. The strategy of PEG grafting CAF09 for the induction
of CD8+ T-cell responses upon s.c. or i.m. administration is promising,
which may accomplish signiﬁcant CD8+ T-cell responses through fur-
ther optimization of the design of the PEG-peptides and the liposomal
formulations.
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